Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker

4 Feb 2019

Abstract excerpt

Analysis of circulating tumour DNA (ctDNA), as one type of 'liquid biopsy', has recently attracted great attention. Researchers are exploring many potential applications of liquid biopsy in many different types of cancer. In particular, it is of biological interest and clinical relevance to study the molecular characteristics of ctDNA. For such purposes, plasma Epstein-Barr virus (EBV) DNA from patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Tumors and Oncological Cases
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30714167
DOI: 10.1002/path.5249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA markerPMID 30714167Read ↗

Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinomaSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinomaSemantic proximity Read ↗

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasmaSemantic proximity Read ↗

Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive populationSemantic proximity Read ↗

Evaluation of plasma Epstein‐Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high‐risk populations in Southern ChinaSemantic proximity Read ↗

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseasesSemantic proximity Read ↗

Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmesSemantic proximity Read ↗

Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretationSemantic proximity Read ↗

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.